肝素诱导的血小板减少症研究进展

[1]	Salter BS,Weiner MM,Trinh MA,et al.Heparin-induced thrombocytopenia:a comprehensive clinical review[J].J Am Coll Cardiol,2016,67:2519-2532.
[2]	Cuker A,Cines DB.How I treat heparin-induced thrombocytopenia[J].Blood,2012,119:2209-2218.
[3]	Kam T,Alexander M.Drug-induced immune thrombocytopenia[J].J Pharm Pract,2014,27:430-439.
[4]	Singla A,Amini MR,Alpert MA,et al.Fatal anaphylactoid reaction associated with heparin-induced thrombocytopenia[J].Vasc Med,2013,18:136-138.
[5]	Cuker A,Arepally G,Crowther MA,et al.The HIT Expert Probability(HEP)Score:a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion[J].J Thromb Haemost,2010,8:2642-2650.
[6]	Pouplard C,Leroux D,Regina S,et al.Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies[J].Thromb Haemost,2010,103:145-150.
[7]	Warkentin TE,Arnold DM,Nazi I,et al.The platelet serotonin-release assay[J].Am J Hematol,2015,90:564-572.
[8]	Padmanabhan A,Jones CG,Curtis BR,et al.A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis[J].Chest,2016,150:506-515.
[9]	Cosmi B.Current management of heparin-induced thrombocytopenia[J].Expert Rev Hematol,2015,8:837-849.
[10]	Goel R,Ness PM,Takemoto CM,et al.Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality[J].Blood,2015,125:1470-1476.
[11]	Watson H,Davidson S,Keeling D.Guidelines on the diagnosis and management of heparin-induced thrombocytopenia:second edition[J].Br J Haematol,2012,159:528-540.
[12]	Kelton JG,Arnold DM,Bates SM.Nonheparin anticoagulants for heparin-induced thrombocytopenia[J].N Engl J Med,2013,368:737-744.
[13]	Bain J,Meyer A.Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia[J].Am J Health Syst Pharm,2015,72:S104-S109.
[14]	Joseph L,Casanegra AI,Dhariwal M,et al.Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia[J].J Thromb Haemost,2014,12:1044-1053.
[15]	Skrupky LP,Smith JR,Deal EN,et al.Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia[J].Pharmacotherapy,2010,30:1229-1238.
[16]	Arepally GM,Ortel TL.Heparin-induced thrombocytopenia[J].Annu Rev Med,2010,61:77-90.
[17]	Warkentin TE.Agents for the treatment of heparin-induced thrombocytopenia[J].Hematol Oncol Clin North Am,2010,24:755-775,ix.
[18]	Parlar AI,Sayar U,Cevirme D,et al.Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery[J].Int J Artif Organs,2014,37:344-347.
[19]	Mavrakanas T,Bounameaux H.The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism[J].Pharmacol Ther,2011,130:46-58.
[20]	Skelley JW,Kyle JA,Roberts RA.Novel oral anticoagulants for heparin-induced thrombocytopenia[J].J Thromb Thrombolysis,2016,42:172-178.